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By means of a complex receptor array, Natural killer (NK) cells can recognize variable
patterns of ligands and regulate or amplify accordingly their effector functions. Such NK
receptors include old, rather conserved, molecules, such as toll-like receptors (TLRs), which
enable NK cells to respond both to viral and bacterial products, and newer and evolving
molecules, such as killer Ig-like receptors and natural cytotoxicity receptors, which control
NK cytotoxicity and are responsible for the elimination of virus-infected or tumor cells with-
out damaging self-unaltered cells. In addition, to rapidly gain new functions NK cells also
can acquire new receptors by trogocytosis. Thus, NK cells may have adapted their recep-
tors to different functional needs making them able to play a key role in the modulation
of critical events occurring in several compartments of human body (primarily in SLCs but
also in decidua during pregnancy). In this review, we will discuss on how the various types
of receptors can be used to address specific functions in different immunological contexts.
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INTRODUCTION
Natural killer (NK) cells are innate lymphocytes present in all
mammalian species capable of mediating multiple effector func-
tions. NK cells express a number of receptors through which
they can directly recognize microbial products, can sense aber-
rant/transformed cells [which lack constitutive self-human leuko-
cyte antigen (HLA)-I molecules and express ligands for activating
NK receptors], or even mediate regulatory functions (being an
early source of cytokines) (1, 2).
Despite the original definition of NK cells based on their “nat-
ural” cytotoxicity against transformed cells in the absence of prior
immunization, several studies indicate that NK cells require edu-
cation/maturation process before killing and carrying out their
biological functions (3).
Specialized NK subsets, which display distinct functions
according to their typical cell-surface phenotype, exist. In partic-
ular, the CD56bright NK cell subset presents little cytolytic activity
but releases high amounts of cytokines, whereas CD56dim NK
cell subset displays potent cytotoxicity but also high cytokine
production in response to specific stimuli (4–6).
The former subset is characterized by the CD16−KIR−NKG2A+
phenotype and largely predominates in lymph nodes, according to
the expression of CCR7 (the homing receptor for secondary lym-
phoid compartments, SLCs) (7, 8), whereas the latter subset is
CD16+KIR+ and/or NKG2A+ and prevails in peripheral blood
and inflamed tissues where they can be recruited, thanks to the
expression of the CXCR1, CX3CR1, and ChemR23 chemokine
receptors (4, 9, 10).
Thus, during the early phases of an inflammatory response,
CD56dim NK cells may be recruited into inflamed tissues in
response to various chemokines. Notably, the extravasation of
NK cells do not imply their activation, thus these cells, once
reached inflammatory sites, need to be activated to carry out their
full effector functions (9). Candidates for NK cell activation are
cytokines, released by innate cells, which are known to interact
with NK cells (e.g., IL12), and/or engagement of certain activat-
ing receptors, including toll-like receptors (TLRs) and/or natural
cytotoxicity receptors (NCRs) (11–14).
The stimulatory activity mediated by these receptors can induce
NK cell-mediated lysis of tumor/virus-infected cells, the release of
pro-inflammatory cytokines and, importantly, can promote the
interactions of NK cells with other innate cells (15–17). This latter
event can help to boost the innate immune system and promote
the development of efficient adaptive immune responses (18).
In this review, the contribution of the different types of NK
cell receptors in NK cell activation and their cooperation has been
analyzed. In addition, new mechanisms of cell communication
that allow the acquisition of unexpected receptor functions and/or
novel functional properties have been described (7, 19, 20).
These novel aspects, probably occurring in response to envi-
ronmental stress such as viral or bacterial infections, disclose new
potential implications of NK cells in physiologic and pathologic
conditions.
TOLL-LIKE RECEPTORS
Toll-like receptors belong to pattern-recognition receptors (PRRs),
which have evolved to recognize conserved features of microbes,
the so-called pathogen-associated molecular patterns (PAMPs)
(21, 22). TLRs are expressed on NK cells independently of their
state of activation and can synergize with chemokine- or cytokine-
mediated signals to activate NK cell function (Table 1A). Both NK
cells and other innate cells express certain TLRs, thus allowing a
coordinated response to the same pathogen-derived product. For
example, viral dsRNA can act on TLR3 expressed by both myeloid
dendritic cells (DCs) and NK cells, recruited by chemokine gradi-
ents to inflammatory sites. In the presence of IL12 (released by DCs
www.frontiersin.org March 2014 | Volume 5 | Article 105 | 1
Sivori et al. Cooperation between NK cell receptors
Table 1 | (A)TLRs expressed by human NK cells and relative ligands: effect of their interaction; (B) NCRs expressed by human NK cells and
relative ligands: effect of their interaction; (C) KIRs expressed by human NK cells and relative ligands: effect of their interaction.
Ligand(s) type Ligand(s) expression Effect of receptor/ligand
interaction
(A)TLR
TLR2 Bacterial lipoprotein (BCG) Bacteria (27, 28) Induction of cytotoxicity and
cytokine release
TLR3 Double-stranded RNA Viruses (13) Induction of cytotoxicity and
cytokine release
TLR5 Flagellin Bacteria (33) Induction of cytotoxicity and
cytokine release
TLR7/8 Single-stranded RNA Viruses (34, 35) Induction of cytotoxicity and
cytokine release
TLR9 CpG DNA motifs Bacteria/viruses (13) Induction of cytotoxicity and
cytokine release
(B) NCR
NKp30 B7-H6 Tumor cells (40) Activation (cytokine/cytotoxicity)
Monocytes/neutrophils (48) (induced by
TLR engagement)
Activation/regulation?
BAT3/BAG6 Tumor cells (39) Activation (cytokine/cytotoxicity)
DC (47) (induced by TLR engagement) Activation of NK/DC cross-talk
ECTV HA Infected cells (44) N.D.
VV HA Infected cells (44) Inhibition
NKp44 21spe-MLL5 Tumor cells (41) Activation (cytokine/cytotoxicity)
Influenza virus-HA; Sendai virus-HN Infected cells (42) Activation (cytokine/cytotoxicity)
PCNA Induced on tumor cells (114) Inhibition
N.D. N.D. IL-22 and TNFα release by ILC3
N.D. BCG (29) Supporting of NK cell activation
N.D. Trophoblasts (73, 74) Activation (cytotoxicity)
NKp46 N.D. Tumor cells (14, 37) Activation (cytokine/cytotoxicity)
Influenza virus-HA; Sendai virus-HN Infected cells (38, 44) Activation (cytokine/cytotoxicity)
N.D. CMV-infected DC (51) Activation (cytokine/cytotoxicity)
NDV-HN Infected tumor cells (115) Activation (cytokine/cytotoxicity)
N.D. Trophoblasts (73, 74) Chemokine production by dNK
(C) KIR
2DL1 C2 epitope Normal cells Inhibition
2DL2/DL3 C1/C2 epitope; few HLA-B (C1 epitope) Normal cells Inhibition
2DL4 HLA-G Normal cells Inhibition/IFNγ induction
CpG ODN (+ +) Infected cells? N.D.
2DL5 N.D. N.D. Inhibition
2DS1 C2 epitope Normal cells; Tumor cells Activation (cytokine/cytotoxicity)
2DS2 N.D. N.D. N.D.
2DS3 N.D. N.D. N.D.
2DS4 N.D. Melanoma cell lines; primary melanoma Activation (cytokine/cytotoxicity)
HLA-A11; some C1 and C2 HLA-C N.D. Activation (cytokine/cytotoxicity)
2DS5 N.D. N.D. N.D.
3DL1 HLA-B and HLA-A (Bw4+) Normal cells Inhibition
CpG ODN (+ + +) Infected cells? N.D.
3DL2 HLA-A3, −A11 Normal cells Inhibition
CpG ODN (+ + +) Infected cells? Activation (cytokine/cytotoxicity)
3DL3 N.D. N.D. N.D.
3DS1 CpG ODN (+ + +) Infected cells? N.D.
HIV-peptides?; HCV-peptides? Infected cells? N.D.
ECTV, ecteromelia virus; VV, vaccinia virus; NDV, new castle disease virus; dNK, decidual NK cells; N.D., not determined.
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after TLR3 stimulation), NK cells respond to dsRNA by improv-
ing their killing capabilities: not only against abnormal target cells,
but also against immature DCs (iDCs) (13). This latter effect has
been proposed as a mechanism by which NK cells can “edit” the
process of DC maturation by selecting those DCs that are undergo-
ing appropriate maturation and therefore would best prime T cells
after migration to SLCs (23, 24). Moreover, upon the simultaneous
stimulation by TLR3 engagement and IL12, NK cells also increase
their capability of secreting pro-inflammatory cytokines, which
mediate several important functions, including promotion of fur-
ther DC maturation, anti-viral/anti-tumor effects, and induction
of Th1 responses (13, 15, 18).
Similar to DCs, NK cells also express TLR2, specific for prod-
ucts of bacterial origin (25). TLR2 is directly involved in the
NK-mediated recognition of Mycobacterium tuberculosis (BCG)
by NK cells (26–28). In turn, DCs, when exposed to BCG, release
large amounts of IL12 that induce an amplification of the effec-
tor functions of NK cells. These include the enhancement of the
NK cell cytotoxicity against both tumor cells and iDCs, and the
cytokine release that can promote maturation of DCs, capable of
inducing adaptive Th1 immune responses (27).
Moreover, the TLR2-mediated interaction of NK cells with BCG
may induce the NK cell expression of NKp44, which, in turn,
can directly bind to BCG (29). However, while TLR2 binding to
Mycobacterium cell wall is sufficient to induce activation of NK
cell effector functions (including IFN-γ production), the engage-
ment of NKp44 by BCG cell wall components may play a role in
maintaining NK cell activation (28).
In addition, it has been recently demonstrated that TLR2
may be also involved in the NK-mediated response to human
CMV (30).
Microbial unmethylated CpG DNA motifs are able to stimulate
both NK cells and plasmacytoid DCs (pDCs) via TLR9, which is,
indeed, expressed by both cell types. IFN-α, released by pDCs upon
TLR9 engagement, supports the triggering of TLR9-responsive NK
cells (31, 32). This activation may be further amplified by IL12,
released by DCs (31).
It has been reported that NK cells may also express TLR5. Fla-
gellin, a typical TLR5 ligand, may directly act on NK cells, and
induces the release of IFN-γ, contributing to activate surrounding
cells, and α-defensins, mediating pathogen destruction (33).
Human NK cells may also express functional TLR7 and TLR8
(34). In this context, it has been shown that NK cell stimulation by
the TLR7/8 ligand ssRNA derived from HIV-1 depends on a direct
contact between NK cells and pDCs or monocytes (35).
Thus, although NK cells can be directly activated by some
TLR agonists, the microenvironment in which they lie, during
TLR-mediated activation, may play an important role not only
in the activation of their cytotoxic activity but also in their regu-
latory functions, able to modulate subsequent adaptive immune
responses (11, 22, 36).
NATURAL CYTOTOXICITY RECEPTORS
NKp46, NKp44, and NKp30 were among the first identified acti-
vating receptors on human NK cells. These structurally unrelated
surface molecules were collectively defined as NCRs for their com-
mon ability to strongly activate NK cell cytolytic activity (37).
The generation of NCR-specific blocking monoclonal antibod-
ies (mAbs) and the identification of an NCRdim-phenotype (with
impaired NK-mediated tumor killing capabilities) in some indi-
viduals (14), rapidly allowed the demonstration that these recep-
tors were recognizing ligands on a large array of NK-susceptible
targets, primarily tumor cells. The first NCR ligands to be discov-
ered, however, were of viral origin (38), while only recently some
of the tumor-expressed cellular ligands (39–41) have been iden-
tified (Table 1B). Different viral hemagglutinins (HAs) bind one
or more NCRs and trigger NK cell functions (42). The pressure
exerted by NCRs on viruses is witnessed by the onset of specific
escape mechanisms (43, 44). Thus, for example, the CMV-encoded
pp65 molecule gives rise to intracellular inhibitory interaction
with NKp30 (43) and the vaccinia virus HA has been recently
shown to bind NKp30 and block NKp30-mediated activation (44).
In addition, NK cells in HIV-infected patients may show various
alterations, including a reduced expression and function of NCRs
(45, 46).
The so far identified tumor-expressed NCR-ligands are repre-
sented by self-antigens whose expression/exposure at the outer
cell surface can be induced by cell stress or activation, or
by still unknown mechanisms related to tumor transformation
(Table 1B). Thus, the NKp30-ligand HLA-B-associated transcript-
3/BCL-2-associated athanogene 6 (BAT3/BAG6) is a nuclear factor
that can be released via exosomes and exposed at the cell surface
by many tumor cells or, in response to stress, by DCs (39, 47).
Another known ligand of NKp30, B7-H6, is expressed on trans-
formed cells, and its expression can also be induced on normal
cells (including monocytes and neutrophils) following stimula-
tion with TLR ligands or pro-inflammatory cytokines (40, 48).
Finally, an NKp44-ligand has been identified as an exon 21spe-
containing isoform (21spe) of mixed lineage leukemia-5 (MLL5)
protein. While the MLL5 is expressed in the nucleus of normal cells
and is involved in the regulation of cell cycle and hematopoietic
differentiation, the 21spe-MLL5 is located in the cytoplasm and at
the cell surface, where it cannot conceivably exert its physiologic
function (41). Remarkably, this isoform appears to be exclusively
transcribed in tumor cells.
Although it is presently unknown whether the tumor-
associated NCR-ligands could also be induced by viral infections,
there are evidences that certain viruses, such as filovirus or HIV,
can promote the expression of still undefined NKp46- or NKp30-
ligands on DCs or T cells (49, 50) Moreover, CMV-infected DCs
can activate NK cells via NKp46 and DNAM-1 (51). Intriguingly,
the mAb recognizing 21spe-MLL5 had been previously shown to
react with CD4+ T cells treated with a specific peptide of HIV
gp41 protein or derived from HIV-infected patients (50). Whatever
could be the pathogenic process that mainly shapes the specificity
of the NCRs, it is quite evident that these receptors are nevertheless
involved in tumor surveillance in vivo. Experiments on NKp46KO
mice support this evidence (52). In addition, various human stud-
ies have shown that both solid and hematologic malignancies can
be frequently associated to the presence of NCRdim NK cells (either
in PB or at the tumor site) (53–56). In this context,different tumor-
orchestrated mechanisms capable of suppressing NCR function-
ality have been described. Hypoxia, which frequently characterizes
tumor tissues (57), or various factors produced by tumor cells or
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induced on by-stander cells, can down-regulate NCR expression
or function. These factors include: IDO, TGFβ, PGE2 (58–60),
or inhibitory NCR-ligands, such as the soluble form of BAT3
(61), and the proliferating cell nuclear antigene (PCNA) (which
has been recently shown to induce NKp44-mediated inhibitory
signaling) (see also Table 1B).
Besides inducing natural cytotoxicity, the NCRs can also
orchestrate regulatory functions. Indeed, since their first dis-
covery, these receptors were known to induce cytokine release.
In addition, in the early 2000s NK cells were shown to par-
ticipate to regulatory interactions with DCs, pDCs, neutrophils,
macrophages, and T cells, involving the engagement of various
receptors including NKp30 and/or NKp46 (12, 58, 62–67). Finally,
over the past 10–15 years, different NCR-expressing NK cell types,
poorly cytolytic, and prominently devoted to regulatory functions,
have been described. According to recent findings, these various
NK cell types and the classical NK cells appear to be part of
the larger family of innate lymphoid cells (ILCs), which show, as
unifying trait, the expression of the transcriptional repressor Id2
during their development from a putative common hematopoi-
etic precursor (68, 69). The different ILCs can be induced in
selected tissues and are characterized by unique cytokine pat-
terns and surface phenotypic profiles (including or not NK cell
markers). Roughly, in both mice and humans, three groups of
ILCs, ILC-group 1, 2, or 3, can be defined according to their abil-
ity to release Th1-, Th2-, or Th17/22-type cytokines respectively.
NK or NK-like cells are comprised within group 1 and 3. The
ILC-group 1 includes classical circulating CD56dimCD16+ NK
cells, and CD56brightCD16dim cells (which prominently populate
lymph nodes). Both these cell types can produce large amounts of
IFN-γ and TNF-α upon NCR engagement (6). The ILC-group 3
includes the CD56+/−NKp44+NKp46+ IL-22-producing NK-like
cells (NCR+ILC3), which populate mucosal tissues. NCR+ILC3
are not cytotoxic but, by producing cytokines including IL-22,
maintain epithelial-cell barrier function and contrast bacterial dis-
semination. The role of NCR on these cells is still poorly defined,
however, a recent report by Glazer et al. (70) indicated that NKp44
engagement could both induce TNF-α release and synergize with
other cytokines to induce IL-22 production.
Another poorly cytotoxic NK cell population endowed with
regulatory functions is represented by CD56brightCD16dimNCR+
NK cells that populate the decidua in the first trimester of
pregnancy. These cells produce defined pattern of cytokines,
chemokines, and pro-angiogenic factors [favoring the appropri-
ate placenta and fetus development (71)], and participate at the
induction of tolerance at the maternal/fetal interface (72). The
interaction with trophoblasts by the engagement of NCRs would
activate their regulatory functions (73, 74). Thus, the definition
of the above-described NCR+ NK cell types, along with their
new functions, would suggest that NCRs could recognize ligands
expressed on different cells, to fulfill multiple tasks. In this context,
for each receptor, different portions of the molecule and/or dif-
ferent polymorphism may have been shaped or selected to ensure
the putative pleiotropy of NCRs (75–77).
HLA-SPECIFIC RECEPTORS: KIRs
Natural killer cells are equipped with inhibitory receptors able to
interact specifically with human leukocyte antigen (HLA) class-I
molecules on potential target cells. These receptors prevent NK
cell-mediated attack against normal autologous cells and allow
the killing of cells that upon tumor transformation or viral infec-
tion present compromised HLA class-I expression (“missing self
hypothesis”) (78) (Figure 1). In humans, two different types of
HLA class-I-specific inhibitory receptors exist: (i) killer Ig-like
receptors (KIRs), also referred to as CD158, that belong to the
Ig-superfamily and, in most instances, recognize the polymorphic
HLA-A, -B, and -C molecules (79–81), and (ii) CD94/NKG2A
(CD94/CD159a), a heterodimer related to C-type lectins that rec-
ognizes HLA-E (82), a non-classical MHC molecule characterized
by a limited polymorphism.
In addition, activating forms of KIRs have been also identi-
fied, but their specificity is still largely elusive (see relating para-
graph). Related to the function performed, the intracytoplasmatic
domains of KIRs can feature either a short (activating KIRs)
or a long (inhibitory KIRs) cytoplasmic tail, “S” or “L” in the
nomenclature, respectively (79, 83) (Table 1C).
Each individual may differ strongly in the activating KIR con-
tent. In particular, two different types of KIR haplotypes (A and B)
can be distinguished in humans. Both haplotypes share inhibitory
KIRs, but haplotype A (in 50% of individuals) includes a single
activating KIR (KIR2DS4) whereas haplotype B has up to five acti-
vating KIRs (83, 84). In general, haplotypes A are beneficial in NK
responses to pathogens, whereas haplotypes B are associated with
low frequencies of pregnancy disorders (85, 86).
In humans, 13 KIR genes and 2 KIR pseudogenes (KIR2DP1
and 3DP1) are expressed. Three conserved genes (KIR3DL3, 2DL4,
and 3DL2) form the common framework.
Only some of the 13 human KIRs have been demonstrated to
recognize HLA class I. In contrast, no ligand has yet been identified
for KIR2DS2, 2DS3, 2DS5, 2DL5, 3DS1, and 3DL3 (87)(Table 1C).
Regarding the Ig-domains content, each KIR displays two
(KIR2D) or three (KIR3D) extracellular Ig-domains. Two types
of KIR2D can be determined. KIR2D of the first type are com-
posed by D1 and D2 domains and include the majority of KIRs
(KIR2DL1/L2/L3 and KIR2DS1/S2/S3/S4/S5), whereas KIR2D of
the second type are composed by D0 and D2 domains and include
KIR2DL4/L5.
The high level of polymorphism in the KIR gene complex
and the low conservation of KIR genes between species (only the
three KIR genes KIR2DL4, KIR2DS4, KIR2DL5 have been pre-
served through hominid evolution) have suggested that KIRs have
been undergone to a rapid evolution (87). Following this process,
new KIR alleles, generated from existing ones under evolutionary
pressure, are likely maintained when providing advantages (88).
A clear diversity in the KIR gene complex between modern
populations indicates that geographically distinct diseases have
recently exerted a selection on KIR repertoires (89).
In addition, the KIR diversification is thought to be more rapid
than HLA diversification. Indeed, HLA genes are more similar in
humans and chimpanzees than their KIR counterparts. In humans,
HLA-C seems to have evolved as a superior and more specialized
ligand for KIRs as compared to HLA-A and -B. This fact is sup-
ported by two considerations: (i) all HLA-C allotypes are KIR
ligands, whereas only 45% of HLA-A and 36% of HLA-B allotypes
are recognized by KIRs and (ii) HLA-C is of more recent origin as
compared to HLA-A and -B (90, 91).
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FIGURE 1 | Different roles for KIRs.
KIRs AS SENSOR FOR MICROBIAL PRODUCTS
Recently, KIRs have been shown to exert a novel and surpris-
ing function. Indeed, primarily KIR3DL2 (but also other KIRs,
including KIR3DL1, KIR3DS1, and KIR2DL4) has been shown
to work as sensors for microbial products and as chaperons for
TLR9 ligands. In particular, KIR3DL2 can bind CpG ODNs at the
NK cell surface and shuttle them to early endosomes where TLR9
translocates upon CpG ODN cell stimulation. In this intracellular
compartment, KIR3DL2 gives CpG ODN to TLR9, thus allowing
NK cell activation both in terms of increment of cytotoxicity and
cytokine production (11, 19) (Figure 1).
The KIR Ig-domain involved in the direct recognition of micro-
bial CpG ODN is represented by the D0, which is expressed by all
the CpG ODN-binding KIRs. The interactions between negative
charges of DNA sequences and positive charges of D0 domain
probably are responsible for this binding. Remarkably, IFN-γ
release induced by CpG ODN stimulation was mostly confined
to KIR3DL2+ NK cell subset, suggesting that this receptor may be
more efficient in CpG ODN-shuttling and NK cell triggering than
the other CpG ODN-binding KIRs (19).
In this context, it is worth noting that KIR3DL2 represents
a framework gene (92) and, as a consequence, NK cells of all
individuals can bind CpG ODN. This novel functional capabil-
ity of KIR3DL2 may provide an important clue to understanding
the driving forces that led to conservation of KIR3DL2-encoding
gene in all haplotypes, in spite of the low frequency of its HLA
ligands (HLA-A3 or -A11 alleles) (93) in the human population.
Indeed, the need of rapid NK-mediated anti-microbial responses
may represent an important factor of selective pressure. Moreover,
KIR3DL2 is characterized by poor inhibitory capability because of
its low affinity for HLA-A ligands. This weak inhibitory function
may explain why KIR3DL2, in most NK cells, is coexpressed with
other inhibitory KIRs or NKG2A (19).
Remarkably, some studies have indicated a three-domain sur-
face molecule carrying a D0 domain as the putative ancestral mam-
malian KIR and have suggested that all KIR2D encoding genes
have evolved from a KIR3D-encoding gene. Considering these
evidences, it is possible to hypothesize that, in origin, certain KIRs
could have a role different from that to recognize MHC-class-I
molecules (94).
ACTIVATING KIRs AS SENTINELS DURING VIRAL
INFECTIONS?
The main differences between activating and inhibitory HLA-
specific receptors are located in their cytoplasmic tails. Indeed,
the activating KIRs are characterized by a short cytoplasmic tail
devoid of ITIMs and by a transmembrane domain with a charged
amino-acid residue that allows association with an ITAM-bearing
molecule (79, 95). The role of activating KIRs in immune response
is still enigmatic and so far little information about it is available.
Only for two of them (KIR2DS1 and KIR2DS4) the specificity for
HLA class-I molecules has been demonstrated (96–100), despite
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their extracellular domains are characterized by a high degree of
sequence homology with their inhibitory counterparts.
However, a number of experimental evidences suggest that acti-
vating KIRs may play a role in NK-mediated response against viral
infections (Figure 1). In particular, protection against hepatitis C
virus infection (101) and delayed progression to AIDS (102) have
been described in individuals coexpressing the activating receptor
KIR3DS1 and its putative ligand, HLA-Bw4 with an isoleucine at
position 80 (HLA-Bw4-80I). In addition, high levels of degranu-
lation by KIR3DS1+ NK cells in response to HIV-infected HLA-
Bw4-80I+ CD4+ T cells (103) and a preferential expansion of
KIR3DS1+NK cells in HLA-Bw4-80I+ subjects during acute HIV-
1 infection (104, 105) have been observed. However, the direct
physical interaction between KIR3DS1 and HLA-Bw4-80I has not
been demonstrated (106).
Moreover, different studies have suggested that the activating
KIRs may interact with HLA class I at a lower affinity than their
inhibitory counterparts. However, during viral infections, their
HLA affinity may be increased by the presentation of viral pep-
tides, thus allowing NK-mediated killing of infected cells (105).
Thus, activating KIRs function could be modulated by the nature
of the HLA class I presented peptide. In this context, KIR2DS1 has
been described to display a certain degree of peptide selectivity in
its binding to HLA-Cw4 (97).
It has been also speculated that additional molecules, up-
regulated on target cells upon cellular stress/transformation, may
also favor the triggering signals delivered by activating KIRs, act-
ing as costimuli, or as non-HLA class-I ligands for these receptors.
Notably, KIR2DS4 is able to interact with a non-HLA class-
I protein expressed on melanoma cell lines and on a primary
melanoma (107).
In some individuals, the increment in the signals generated by
the low-affinity activating KIRs may overcome normal NK cell
self-tolerance, thus inducing autoimmune diseases (108).
KIR AS A PROMOTER OR DAMPER FOR A PHENOTYPE
CHANGE
Since cellular function is often linked to phenotype, it is of
particular interest that the recent discovery of a mechanism by
which NK cells would be able to capture target cell membrane
components, and incorporate them in its own membrane, thus
enriching their phenotypic/functional features (109). This process,
known as trogocytosis, involves several cell-surface molecules in
different cell types including lymphocytes as well as DCs and
tumor cells and may represent a vector for rapid intercellu-
lar communication (110). The capture of target cell membrane
fragments by NK cells is likely to reflect specific ligand recog-
nition by NK cell receptors and, in particular, activating and
inhibitory receptors control this process. Importantly, surface mol-
ecules acquired from other cell types could modify not only
phenotypic but also functional characteristics of the recipient
cells (111).
Through this mechanism, some peculiar characteristics of the
two major NK cell subsets (CD56dim/CD56bright) (10) can be sub-
verted. In this context, recently, it has been shown that the highly
cytotoxic CD56dim KIR+ NK cell subpopulation that is char-
acterized by the CCR7− phenotype, can acquire surface CCR7
upon interaction with CCR7+ cells, becoming able to migrate in
response to the SLC chemokines CCL19/CCL21 (7).
This novel NK cell ability occurs via the immunological
synapse, precedes the NK-mediated cytolysis, and is finely con-
trolled by the specific interaction between KIRs on NK cells and
HLA class-I molecules on CCR7+ cells. In particular, inhibitory
KIRs block this transfer (7), whereas activating KIRs (e.g.,
KIR2DS1) are able to strongly promote the CCR7 acquisition by
NK cells (8, 20). In addition, other surface NK receptors, includ-
ing the NCR NKp46, may play a crucial role in promoting this
phenomenon (7). Therefore, in some individuals, collaboration
between activating KIRs and other non-HLA-specific triggering
receptors may occur to further potentiate the CCR7 acquisition.
Remarkably, unlike the non-HLA-specific receptors (whose
function could be limited by inhibitory signals delivered by both
KIRs/NKG2A receptors), KIR2DS1 could promote CCR7 uptake
even in NKG2A+ NK cells, since the KIR2DS1-dependent uptake
of CCR7 can override the inhibition provided by this receptor.
This event allows a substantial expansion of the NK cell fraction
capable of migrating to lymph nodes (20).
The key role of KIRs during the CCR7 transfer has important
implications during haploidentical hematopoietic stem cell trans-
plantation, in which donor-derived alloreactive NK cells express-
ing KIRs may play a relevant role in preventing graft vs. host disease
(by killing recipient DCs) and host vs. graft reactions (by killing
recipient T cells) (112). However, because KIR+ NK cells normally
do not express CCR7, it was unclear how alloreactive KIR+ NK
cells could reach lymph nodes and kill these cells directly in this
compartment. In this context, the CCR7 acquisition by trogocyto-
sis may represent a new way by which alloreactive KIR+ NK cells
can migrate to the site where they can kill mature DCs and T cell
blasts (20, 113) (Figure 1).
CONCLUSION
Several data have demonstrated that the different NK cell recep-
tors can reciprocally coordinate and regulate their functions,
contributing to the initiation of innate responses and to the subse-
quent priming of adaptive immune responses. NK cell activation
may be mediated by the engagement of TLRs and/or NCRs, two
different types of receptors that may cooperate in inducing NK
cell triggering, and thus in controlling viral/bacterial infection
and cancer. For example, it has been demonstrated that TLR2 and
NKp44 are directly involved in the recognition of Mycobacterium
and in the consequent promotion of NK cell effector functions
(28).
Natural killer cell triggering is under the control of receptors
(e.g., KIRs) specific for self-HLA class-I molecules. The missing
recognition of specific HLA ligands by inhibitory KIRs enables
NK cell triggering upon NCRs engagement (37). Most tumor cell-
surface ligands for NCRs have remained elusive; however, a critical
role for NCRs in the control of both tumors and viral infections
has been clearly demonstrated.
On the other hand, collaboration between TLRs and KIRs may
also exist. Indeed, certain KIRs can function as sensor for micro-
bial products and as chaperons for TLR9 ligands. Remarkably, an
inhibitory KIR, such as KIR3DL2, may unexpectedly induce NK
cell activation, favoring TLR-mediated response (19).
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FIGURE 2 | Collaboration model betweenTLRs, KIRs, NCRs for NK cell activation.
Activating and inhibitory NK receptors control other important
mechanisms, such as trogocytosis, by which NK cells can modify
their phenotypic/functional features. For example, KIR+ NK cells
can acquire CCR7 and thus migratory properties toward SLCs,
by interacting with CCR7+ cells (e.g., mature DCs). This process
is blocked by inhibitory KIRs and promoted by NCRs and, even
further, by activating KIRs (7, 20).
The NK-mediated capability of releasing chemokines and
cytokines in different compartments endowed NK cells with
regulatory functions, affecting subsequent adaptive immune
responses. In decidual tissues, the engagement of NCRs during
NK–trophoblast interactions induces the release of regulatory
chemokines, involved in tissue building and remodeling, and in
the formation of new blood vessels (74).
In conclusion, a wide and heterogenous group of receptors
allow NK cell to fulfill multifaceted functions (Figure 2). The
nodes of this intricate functional network may represent new ther-
apeutic targets in different pathological conditions including not
only tumors or infections but also immune-mediated diseases or
pregnancy failure.
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